Daiwa Health Development, Inc. Announces Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC Daiwa Health Development, Inc. is thrilled to host an upcoming webinar featuring Dr. Fred Pescatore, a distinguished expert in integrative medicine. Scheduled for August 29,…
AmorSui, a cutting-edge personal protective equipment (PPE) brand committed to safeguarding both people and the planet, has announced a successful $3.5 million seed funding round. This investment will propel AmorSui’s mission to enhance sustainability, inclusivity, and affordability in the PPE…
Oggi, Agendia ha annunciato di aver ricevuto la certificazione dell’Unione Europea (UE) In vitro Diagnostic Medical Device Regulation (IVDR) per tre dei suoi prodotti: MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray e i kit MammaPrint® e BluePrint® NGS. Questi prodotti sono…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced its unaudited financial results and notable corporate developments for the second quarter of 2024. CEO Statement Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech, commented, “The…
Royalty Pharma today released its financial results for the second quarter of 2024 and announced an increase in its full-year guidance for Portfolio Receipts. We achieved double-digit growth in Portfolio Receipts during the second quarter of 2024, surpassing our quarterly…
Bayer announced today that the FINEARTS-HF trial met its primary endpoint by achieving a statistically significant reduction in the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, including hospitalizations for HF or urgent HF visits.…
Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows a positive opinion from the Committee for Orphan Medicinal Products…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise. Product revenue, which comes entirely from sales of NERLYNX®, Puma’s…
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product revenue guidance to $10.65 to $10.85 billion. “Vertex achieved another…
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.…
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). The goal is to create new tests that measure tau burden in the brain, offering crucial insights into…
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Vertex Pharmaceuticals today revealed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for suzetrigine, an investigational oral NaV1.8 pain signal inhibitor designed to…
